Radhi, S (2020) To Study the Effect of Ormeloxifene in the Regression of Mastalgia and Fibroadeno. Masters thesis, Chengalpattu Medical College and Hospital, Chengalpattu.
|
Text
220100620radhi.pdf Download (3MB) | Preview |
Abstract
Prospective Randomized control study to study the role of ormeloxifene in the regression of mastalgia and fibroadenoma, conducted in the department of General Surgery at Chengalpattu medical college, Chengalpattu. BACKGROUND: Benign breast disease includes mastalgia, fibroadenoma, fibroadenomatous hyperplasia, fibrocystic disease, mastitis, sclerosing adenosis and breast abscess. Patients with benign breast disease often present with pain and swelling . They frequently visit the clinic for the complaints of pain and nodular swelling. Most of the benign breast disease are treated conservatively with medications and rarely surgery. There is no satisfactory treatment for these benign disease My thesis topic is to study the effect of ormeloxifene in the regression of mastalgia & fibroadenoma. Ormeloxifene, also known as centchroman, is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a non-hormonal, nonsteroidal oral contraceptive. OBJECTIVES: 1. To study the effect of Ormeloxifene in the regression of mastalgia & fibroadenoma. 2. To study the time taken for the healing of benign breast diseases with the use of Ormeloxifene. METHOD OF THE STUDY: Hundred patients in the department of General Surgery , with complaints of breast pain and lump are selected and randomly divided into two group. One group was treated with Ormeloxifene 30mg twice a wk for 12 wks and the other group with placebo such as vitamin tablets for 12 wks. The effect was assessed with pain scale, breast lump size with Lucknow –Cardiff scale and with Ultrasound breasts. RESULTS: The patients who are treated with ormeloxifene for mastalgia and fibroadenoma shows pain relief and reduction in nodularity respectively. 92% of mastalgia patients showed response to ormeloxifene, whereas 80% of nodularity reduced completely with ormeloxifene at the end of 12 weeks. CONCLUSION: Ormeloxifene also known as centchroman, which is a selective estrogen receptor modulator was found to be effective in treating mastalgia and fibroadenoma.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | 221711260 |
| Uncontrolled Keywords: | Ormeloxifene, Regression, Mastalgia, Fibroadeno. |
| Subjects: | MEDICAL > General Surgery |
| Depositing User: | Subramani R |
| Date Deposited: | 10 Feb 2021 17:19 |
| Last Modified: | 10 Feb 2021 17:19 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/14006 |
Actions (login required)
 |
View Item |
